Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by SizzlinSteakson Mar 19, 2018 8:21am

111 Views

Post# 27738032

RE:Big day

Do you have a link for the short position you are referencing? I suspect what you are looking at is the "short volume", not the "short position". These are two very different things.

WaterStreet87 wrote: Per tsx 30 percent roughly of the float is shorted. Once halt goes on and new is positive this will make for an extraordinarily solid short squeeze. Lots of apparent penny flippers here for a few hundred in profits per day it seems. Just block out the noise - can’t imagine anyone with 6 figure portfolio like myself taking advice from a user named Walmart bus line.

Once approval comes in, buyout is imminent. I suspect there’s already companies interested with approval contingency.

Besy of luck - remember halt can happen at any point this week.

Water.